Want to join the conversation?
Samuel Eisner from Goldman Sachs asks about working capital, how $APOG expects it playing out for FY17. $APOG said that on working capital growth in next quarter, there are 2 drivers; reduction of accruals driven by payments of annual incentive comps last year, and timing of receivables. Overall, expect little bit growth in FY17.
Biodefense therapeutics firm $PIP announced an all-stock merger with biotech Altimmune. The respective boards of the two companies unanimously approved the merger.
$YHOO is reporting today after market close. Nobody cares about this stock.